Chemistry:Bivamelagon
From HandWiki
Bivamelagon (INN; developmental code names LB54640, LR-19021) is a small-molecule melanocortin MC4 receptor agonist under development by LG Chem Life Sciences for the treatment of hypothalamic obesity, .[1][2] Unlike the older drug with the same mechanism of action, setmelanotide, it can be taken orally.[3][4][5] As of March 2024, it is in phase 2 clinical trials.[1]
References
- ↑ 1.0 1.1 "Rhythm Pharmaceuticals". 13 March 2024. https://adisinsight.springer.com/drugs/800075476.
- ↑ "Delving into the Latest Updates on Bivamelagon with Synapse". 23 January 2025. https://synapse.patsnap.com/drug/bdf83058ad9643009c893b732c617882.
- ↑ Aronne, Sarah R. Barenbaum, Louis J. (2023). "Antiobesity Medications on the Horizon". Handbook of Obesity - Volume 2 (5 ed.). CRC Press. pp. 394–401. doi:10.1201/9781003432807-42. ISBN 978-1-003-43280-7. https://www.taylorfrancis.com/chapters/edit/10.1201/9781003432807-42/antiobesity-medications-horizon-sarah-barenbaum-louis-aronne.
- ↑ First-in-Human Study of Safety, Pharmacodynamics of LB54640, An Oral Melanocortin-4 Receptor Agonist Mirza, Victoria, MD, MPH; Lee, Jisoo, MD; Gwak, Heemin; Yang, Yunjeong; Kim, Mina. Obesity; Silver Spring Vol. 30, (Nov 2022): 145-146.
- ↑ Piper, Noah B.C.; Whitfield, Emily A.; Stewart, Gregory D.; Xu, Xiaomeng; Furness, Sebastian G.B. (August 2022). "Targeting appetite and satiety in diabetes and obesity, via G protein-coupled receptors". Biochemical Pharmacology 202. doi:10.1016/j.bcp.2022.115115. PMID 35671790.
 |  |
